A Real-world Study on the Treatment of Non-small Cell Lung Cancer With Leptomeningeal Metastasis in China
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorGuangzhou Medical University
About this trial
This is a retrospective and prospective study planned to include NSCLC patients with Leptomeningeal metastasis (LM) and treated with antitumor therapy after 2018, from multiple centers such as the First Affiliated Hospital of Guangzhou Medical University, Guangdong Sanjiu Brain Hospital, etc., aiming to establish a database related to the treatment strategies of LM patients, and to evaluate the efficacy (eg. Overall Survival/Time to Failure) and safety of different treatment strategies of LM patients, etc., as well as the significance of concomitant testing in LM patients.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
non-small cell lung cancer patients with Leptomeningeal metastases diagnosed after January 2018;
Patients who underwent antitumor therapy after diagnosis of LM.
Disqualifiers
Patients with small cell lung cancer components;
complicated with tumors other than non-small cell lung cancer.
Trial population
non-small cell lung cancer patients with Leptomeningeal metastases
Trial design
Design model
Cohort
Time perspective
Other
Treatments tested in this trial
Not applicable- observational study
Other interventionThis is a retrospective and observational study. Not Applicable
Treatment groups
No treatment groups listed
Trial outcomes
Primary outcomes
1
Overall survival(OS)
Time frame
6 yearsSecondary outcomes
1
Time to failure(TTF)
Time frame
6 years2
Change in cerebrospinal fluid and metabolic markers during treatment
Time frame
6 years3
Safety during actual clinical treatment
Time frame
6 yearsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov